

Cite as: M. Tabebordbar *et al.*, *Science*  
10.1126/science.aad5177 (2015).

# In vivo gene editing in dystrophic mouse muscle and muscle stem cells

Mohammadsharif Tabebordbar,<sup>1,2\*</sup> Kexian Zhu,<sup>1,3\*</sup> Jason K. W. Cheng,<sup>1</sup> Wei Leong Chew,<sup>2,4</sup> Jeffrey J. Widrick,<sup>5</sup> Winston X. Yan,<sup>6,7</sup> Claire Maesner,<sup>1</sup> Elizabeth Y. Wu,<sup>1†</sup> Ru Xiao,<sup>8</sup> F. Ann Ran,<sup>6,7</sup> Le Cong,<sup>6,7</sup> Feng Zhang,<sup>6,7</sup> Luk H. Vandenberghe,<sup>8</sup> George M. Church,<sup>4</sup> Amy J. Wagers<sup>1‡</sup>

<sup>1</sup>Department of Stem Cell and Regenerative Biology, Harvard University and Harvard Stem Cell Institute, Cambridge, MA 02138, USA. <sup>2</sup>Biological and Biomedical Sciences Program, Harvard Medical School, Boston, MA 02115, USA. <sup>3</sup>Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA. <sup>4</sup>Department of Genetics, Harvard Medical School, Boston, MA 02115, USA. <sup>5</sup>Division of Genetics and Program in Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. <sup>6</sup>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. <sup>7</sup>McGovern Institute for Brain Research, Department of Brain and Cognitive Science, and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. <sup>8</sup>Grousbeck Gene Therapy Center, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, 20 Staniford Street, Boston, MA 02114, USA.

\*These authors contributed equally to this work.

†Present address: RaNA Therapeutics, 200 Sidney Street, Suite 310, Cambridge, MA 02139, USA.

‡Corresponding author. E-mail: amy\_wagers@harvard.edu

**Frame-disrupting mutations in the *DMD* gene, encoding dystrophin, compromise myofiber integrity and drive muscle deterioration in Duchenne muscular dystrophy (DMD). Removing one or more exons from the mutated transcript can produce an in-frame mRNA and a truncated, but still functional, protein. In this study, we develop and test a direct gene-editing approach to induce exon deletion and recover dystrophin expression in the *mdx* mouse model of DMD. Delivery by adeno-associated virus (AAV) of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 endonucleases coupled with paired guide RNAs flanking the mutated *Dmd* exon23 resulted in excision of intervening DNA and restored Dystrophin reading frame in myofibers, cardiomyocytes, and muscle stem cells following local or systemic delivery. AAV-*Dmd* CRISPR-treatment partially recovered muscle functional deficiencies and generated a pool of endogenously corrected myogenic precursors in *mdx* mouse muscle.**

Duchenne muscular dystrophy (DMD) is a progressive muscle degenerative disease caused by point mutations, deletions, or duplications in the *DMD* gene that cause genetic frame-shift or loss of protein expression (1). Efforts under development to reverse the pathological consequences of DYSTROPHIN deficiency in DMD aim to restore its biological function through viral-mediated delivery of genes encoding shortened forms of the protein, upregulation of compensatory proteins, or interference with the splicing machinery to “skip” mutation-carrying exons in the mRNA and produce a truncated, but still functional protein [reviewed in (2)].

The potential efficacy of exon-skipping strategies is supported by the relatively mild disease course of Becker Muscular Dystrophy (BMD) patients with in-frame deletions in *DMD* (3, 4), and by the capacity of antisense oligonucleo-

tides (AONs), which mask splice donor or acceptor sequences of mutated exons in dystrophin mRNA, to restore biologically active DYSTROPHIN protein in mice (5, 6) and humans (7, 8). Yet, limitations remain for the use of AONs, including variable efficiencies of tissue uptake, depending on AON chemistry, a requirement for repeated AON injection to maintain effective skipping, and the potential for AON-associated toxicities [(9, 10) and supplementary text].

Here, we sought to address these limitations by developing a one-time, multisystemic approach based on the genome-editing capabilities of the CRISPR/Cas9 system. This system, coopted originally from *Streptococcus pyogenes* (Sp), couples a DNA double strand endonuclease with short “guide RNAs” (gRNAs) that provide target specificity to any site in the genome that also contains an adjacent ‘NGG’ pro-

tospacer adjacent motif (PAM) (11–14), thereby enabling targeted gene disruption, replacement, and modification.

To apply CRISPR/Cas9 for exon deletion in DMD, we first established a reporter system for CRISPR activity by “repurposing” the existing Ai9 mouse reporter allele, which encodes the fluorescent tdTomato protein downstream of a ubiquitous CAGGS promoter and “floxed” STOP cassette (15, 16) (fig. S1A). Exposure to SpCas9, together with paired gRNAs targeting near the Ai9 loxP sites (hereafter Ai9 gRNAs), resulted in excision of intervening DNA and expression of tdTomato (fig. S1, A, B, and E). We next designed and tested paired gRNAs (hereafter *Dmd23* gRNAs, fig. S1C) directed 5' and 3' of mouse *Dmd* exon23, which in *mdx* mice carries a nonsense mutation that destabilizes *Dmd* mRNA and disrupts DYSTROPHIN expression (17). Finally, we coupled the paired *Dmd23* and Ai9 gRNAs using a two plasmid system that links expression of the CRISPR activity reporter (tdTomato) to genome editing events at the *Dmd* locus (fig. S1D). In vitro transfection of primary satellite cells from *mdx* mice carrying the Ai9 allele (hereafter *mdx;Ai9* mice) with SpCas9 + Ai9-*Dmd23* coupled gRNAs induced gene editing at both the Ai9 locus, demonstrated by tdTomato expression (fig. S1E), and *Dmd* locus, detected by genomic PCR (Fig. 1A) and confirmed by amplicon sequencing (fig. S1F). *Dmd* editing was not detected in *mdx;Ai9* cells receiving Ai9 gRNAs alone (Fig. 1A), although tdTomato expression was equivalently induced (fig. S1E).

To confirm that CRISPR-mediated *Dmd* editing results in irreversible genomic modification and production of exon-deleted mRNA and protein, primary satellite cells from *mdx;Ai9* mice were co-transfected with SpCas9 + Ai9 or Ai9-*Dmd23* gRNAs, FACSsorted based on tdTomato expression, expanded in vitro (18), and differentiated to myotubes. RT-PCR (Fig. 1B) and amplicon sequencing (fig. S1G) from these myotubes detected exon23-deleted *Dmd* mRNA in cells receiving Ai9-*Dmd23* coupled gRNAs, but not in cells receiving only Ai9 gRNAs. Taqman analysis (9) further indicated that exon23-deleted transcripts represented 24–47% of total *Dmd* mRNA in cells receiving Ai9-*Dmd23* coupled gRNAs, whereas exon23 deletion was undetectable with Ai9 gRNAs alone (fig. S1H). DYSTROPHIN protein expression was also restored in CRISPR-modified *mdx;Ai9* cells, as detected by Western blot of in vitro differentiated myotubes (Fig. 1C) and immunostaining of muscle sections from *mdx* mice transplanted with gene-edited *mdx;Ai9* satellite cells (Fig. 1D and fig. S1I). These data demonstrate that CRISPR/Cas9 can direct sequence-specific modification of disease alleles in primary muscle stem cells that retain muscle engraftment capacity.

We next adapted CRISPR for delivery via adeno-associated virus (AAV), employing the smaller Cas9 ortholog

from *Staphylococcus aureus* (SaCas9), which can be packaged in AAV and programmed to target any locus in the genome containing a “NNGRR” PAM sequence (19). We generated Sa gRNAs targeting Ai9 and introduced several base modifications into the gRNA scaffold to enhance gene targeting by SaCas9 (Fig S2, A to C). Using this modified scaffold, we tested *Dmd23* Sa gRNAs (fig. S2D) and produced AAVs encoding SaCas9 and Ai9 Sa gRNAs or *Dmd23* Sa gRNAs in a dual (fig. S3A) or single (fig. S3B) vector system. Comparison of exon23 excision efficiencies in transduced *mdx* myotubes demonstrated more efficient excision by dual AAV-CRISPR (fig. S3, C and D), as compared to single vector AAVs. Therefore, to test the potential for in vivo *Dmd* targeting by CRISPR/Cas9, we pseudotyped dual AAVs (AAV-SaCas9 + AAV-Ai9 gRNAs; hereafter, AAV-Ai9 CRISPR) to serotype 9, which exhibits robust transduction of mouse skeletal and cardiac muscle (20), and injected these AAVs into the tibialis anterior (TA) muscles of *mdx;Ai9* mice (7.5E+11 vg each). Four weeks later, muscles were harvested to assess genome-editing events. TdTomato fluorescence was detected in muscles injected with AAV-Ai9 CRISPR, but not in muscles injected with vehicle alone (fig. S4A). Co-delivery of AAV9-SaCas9 + AAV9-*Dmd23* gRNAs (hereafter AAV-*Dmd* CRISPR) likewise yielded robust and specific modification of the *Dmd* locus in TA muscles in vivo. Genomic PCR (Fig. 2A) and Sanger sequencing (fig. S4B) demonstrated exon23 excision in muscles injected with AAV-*Dmd* CRISPR, but not AAV-Ai9 CRISPR. Next-generation sequencing indicated minimal activity at the predicted highest-ranking genomic off-target sites (fig. S12). RT-PCR (Fig. 2B) and sequencing (fig. S4C) further confirmed the presence of exon23-deleted *Dmd* mRNA in muscles receiving AAV-*Dmd* CRISPR, with an average exon23-excision rate of 39% ±1.8% (fig. S3E). In vivo CRISPR-mediated targeting of *Dmd* exon23 restored DYSTROPHIN expression in skeletal muscle, as detected by Western blot (Fig. 2C), immunofluorescence (Fig. 2D) and capillary immunoassay (fig. S5A). Other pathological hallmarks of dystrophy were also restored in AAV-*Dmd* CRISPR injected muscles, including sarcolemmal localization of the multimeric dystrophin-glycoprotein complex and neuronal nitric-oxide synthase (figs. S6 and S7). In contrast, DYSTROPHIN expression was undetectable by Western (Fig. 2C) and present only on rare revertant fibers in *mdx;Ai9* mice receiving control AAV-Ai9 CRISPR (Fig. 2D) (21). Finally, to evaluate the functional consequences of CRISPR-mediated induction of exon23-deleted DYSTROPHIN, we subjected a subset of *mdx;Ai9* mice injected intramuscularly with AAV-*Dmd* CRISPR to in situ muscle force assessment. Muscles receiving AAV-*Dmd* CRISPR showed significantly increased specific force (Fig. 2E) and attenuated force drop after eccentric damage (Fig. 2F), as compared to contralateral, vehicle-

injected muscles and also AAV-Ai9 CRISPR injected muscles. In contrast, differences in specific force (Fig. 2E) and force drop (Fig. 2F) for AAV-Ai9 CRISPR injected mice were not significantly different between the virus-injected and vehicle-injected muscles.

We next evaluated the potential for multisystemic gene editing in vivo using AAV-CRISPR. Dual AAV-Ai9 CRISPR vectors (1.5E+12 vg each) were co-injected intraperitoneally into *mdx;Ai9* mice at postnatal day 3 (P3). Three weeks later, widespread tdTomato expression was detected in all cardiac and skeletal muscles analyzed (fig. S8A). Parallel injections of *mdx;Ai9* mice with AAV-*Dmd* CRISPR revealed exon23-deleted transcripts in multiple skeletal muscles and cardiac muscle, with targeting levels varying from 3-18% in different muscle groups (and. 3A and fig. S3F). Exon23 was not excised in animals receiving AAV-Ai9 CRISPR instead (Fig. 3A, and figs. S3F and S8B). Finally, Western blot (Fig. 3B and fig. S8C), immunofluorescence (Fig. 3C), and capillary immunoassay (fig. S5B) confirmed that DYSTROPHIN protein was largely absent in muscles of control *mdx;Ai9* mice receiving AAV-Ai9 CRISPR and restored in mice receiving AAV-*Dmd* CRISPR. Similar systemic dissemination of AAV and excision of exon23 in multiple organs were seen in two adult mice injected intravenously with AAV-*Dmd* CRISPR at 6 weeks of age (fig. S9).

Dystrophic pathology and other muscle injuries activate muscle stem cells (also known as satellite cells), leading to regenerative responses that add new nuclei to damaged fibers [(2) and see supplementary text]. To evaluate AAV-CRISPR gene editing in satellite cells in vivo, we crossed *mdx;Ai9* mice with Pax7-ZsGreen animals, in which satellite cells are specifically marked by green fluorescence (22), and injected these animals intramuscularly or systemically with AAV9 encoding Cre (hereafter, AAV-Cre) or Ai9-CRISPR components. Muscles were harvested 2 weeks later (Fig. 4A), and analyzed by FACS. tdTomato expression was apparent in Pax7-ZsGreen<sup>+</sup> satellite cells following local or systemic delivery of AAV-Cre or AAV-Ai9 CRISPR (Fig. 4B and fig. S10, A to C), although excision rates were lower for AAV-Ai9 CRISPR than for AAV-Cre. In vitro differentiation of ZsGreen<sup>+</sup> satellite cells from mice receiving intramuscular or systemic AAV-Cre or AAV-Ai9 CRISPR produced tdTomato<sup>+</sup> myotubes, demonstrating preservation of myogenic potential in AAV-transduced and gene-edited satellite cells (Fig. 4C and fig. S10D). TdTomato<sup>+</sup> gene-edited satellite cells also engrafted recipient *mdx* muscle and contributed to in vivo muscle regeneration after transplantation (fig. S10E).

We next analyzed *Dmd* editing in Pax7-ZsGreen<sup>+</sup> satellite cells following intramuscular or systemic delivery of AAV-*Dmd* CRISPR or AAV-Ai9 CRISPR. Satellite cells were

isolated by FACS, expanded and differentiated in vitro (Fig. 4A). RT-PCR revealed a truncated *Dmd* transcript of the expected size and sequence for gene-edited *Dmd* in satellite cell-derived myotubes from many of the AAV-*Dmd* CRISPR injected muscles, but none of the AAV-Ai9 CRISPR injected muscles (Fig. 4D and fig. S10, F, H, and I). Quantification of exon23-excision revealed variable efficiencies (fig. S10, G and J), likely reflecting targeting of only a subset of endogenous satellite cells that may be variably represented among the isolated and cultured cells. Finally, genomic PCR and amplicon sequencing confirmed targeted excision at the *Dmd* locus in satellite cell-derived myotubes (fig. S10K), and capillary immunoassay analysis revealed restored DYSTROPHIN expression (fig. S10L). As expected, injection of AAV-*Dmd* CRISPR did not induce tdTomato expression in satellite cells or myofibers of *mdx;Ai9* mice (fig. S11).

In summary, this study provides proof-of-concept evidence supporting the efficacy of in vivo genome editing to correct disruptive mutations in DMD in a relevant dystrophic mouse model. We show that programmable CRISPR complexes can be delivered locally and systemically to terminally differentiated skeletal muscle fibers and cardiomyocytes, as well as muscle satellite cells, in neonatal and adult mice, where they mediate targeted gene modification, restore DYSTROPHIN expression and partially recover functional deficiencies of dystrophic muscle. As prior studies in mice and humans indicate that DYSTROPHIN levels as low as 3-15% of wild-type are sufficient to ameliorate pathologic symptoms in the heart and skeletal muscle (23-26), and levels as low as 30% can suppress the dystrophic phenotype altogether (27), the restoration of DYSTROPHIN achieved here by one-time administration of AAV-*Dmd* CRISPR clearly encourages further evaluation and optimization of this system as a new candidate modality for the treatment of DMD (see supplementary text).

## REFERENCES AND NOTES

1. M. Koenig, E. P. Hoffman, C. J. Bertelson, A. P. Monaco, C. Feener, L. M. Kunkel, Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. *Cell* 50, 509-517 (1987). Medline doi:10.1016/0092-8674(87)90504-6
2. M. Tabeboardbar, E. T. Wang, A. J. Wagers, Skeletal muscle degenerative diseases and strategies for therapeutic muscle repair. *Annu. Rev. Pathol.* 8, 441-475 (2013). Medline doi:10.1146/annurev-pathol-011811-132450
3. A. Nakamura, K. Yoshida, K. Fukushima, H. Ueda, N. Urasawa, J. Koyama, Y. Yazaki, M. Yazaki, T. Sakai, S. Haruta, S. Takeda, S. Ikeda, Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. *J. Clin. Neurosci.* 15, 757-763 (2008). Medline doi:10.1016/j.jocn.2006.12.012
4. A. Taglia, R. Petillo, P. D'Ambrosio, E. Picillo, A. Torella, C. Orsini, M. Ergoli, M. Scutifero, L. Passamano, A. Palladino, G. Nigro, L. Politano, Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene. *Acta Myol.* 34, 9-13 (2015). Medline
5. Q. L. Lu, C. J. Mann, F. Lou, G. Bou-Gharios, G. E. Morris, S. A. Xue, S. Fletcher, T. A. Partridge, S. D. Wilton, Functional amounts of dystrophin produced by



- skipping the mutated exon in the mdx dystrophic mouse. *Nat. Med.* **9**, 1009–1014 (2003). Medline doi:10.1038/nm897
6. Y. Echigoya, Y. Aoki, B. Miskew, D. Panesar, A. Touznik, T. Nagata, J. Tanihata, A. Nakamura, K. Nagaraju, T. Yokota, Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45–55 with a cocktail of vivo-morpholinos in mdx52 mice. *Mol. Ther. Nucleic Acids* **4**, e225 (2015). Medline doi:10.1038/mtna.2014.76
  7. J. C. van Deutekom, A. A. Janson, I. B. Ginjaar, W. S. Frankhuizen, A. Aartsma-Rus, M. Bremmer-Bout, J. T. den Dunnen, K. Koop, A. J. van der Kooi, N. M. Goemans, S. J. de Kimpe, P. F. Ekhardt, E. H. Venneker, G. J. Platenburg, J. J. Verschuuren, G. J. van Ommen, Local dystrophin restoration with antisense oligonucleotide PRO051. *N. Engl. J. Med.* **357**, 2677–2686 (2007). Medline doi:10.1056/NEJMoa073108
  8. M. Kinali, V. Arechavala-Gomez, L. Feng, S. Cirak, D. Hunt, C. Adkin, M. Guglieri, E. Ashton, S. Abbs, P. Nihoyannopoulos, M. E. Garralda, M. Rutherford, C. McCulley, L. Popplewell, I. R. Graham, G. Dickson, M. J. Wood, D. J. Wells, S. D. Wilton, R. Kole, V. Straub, K. Bushby, C. Sewry, J. E. Morgan, F. Muntoni, Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, dose-escalation, proof-of-concept study. *Lancet Neurol.* **8**, 918–928 (2009). Medline doi:10.1016/S1474-4422(09)70211-X
  9. A. Goyenvalle, G. Griffith, A. Babbs, S. El Andaloussi, K. Ezzat, A. Avril, B. Dugovic, R. Chausseot, A. Ferry, T. Voit, H. Amthor, C. Bühr, S. Schürch, M. J. Wood, K. E. Davies, C. Vaillend, C. Leumann, L. Garcia, Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. *Nat. Med.* **21**, 270–275 (2015). Medline doi:10.1038/nm3395-015-0070-6
  10. M. C. Vila, M. B. Klimek, J. S. Novak, S. Rayavarapu, K. Jaesoontrachoon, J. F. Boehler, A. A. Fiorillo, M. W. Hogarth, A. Zhang, C. Shaughnessy, H. Gordish-Dressman, U. Burki, V. Straub, Q. L. Lu, T. A. Partridge, K. J. Brown, Y. Hathout, J. van den Anker, E. P. Hoffman, K. Nagaraju, Elusive sources of variability of dystrophin rescue by exon skipping. *Skeletal Muscle* **5**, 44 (2015). Medline doi:10.1186/s13395-015-0070-6
  11. L. Cong, F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini, F. Zhang, Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013). Medline doi:10.1126/science.1231143
  12. P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, G. M. Church, RNA-guided human genome engineering via Cas9. *Science* **339**, 823–826 (2013). Medline doi:10.1126/science.1232033
  13. F. A. Ran, P. D. Hsu, J. Wright, V. Agarwala, D. A. Scott, F. Zhang, Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**, 2281–2308 (2013). Medline doi:10.1038/nprot.2013.143
  14. M. Jinek, K. Chylinski, I. Fontana, M. Hauer, J. A. Doudna, E. Charpentier, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**, 816–821 (2012). Medline doi:10.1126/science.1225829
  15. L. Madisen, T. A. Zwingman, S. M. Sunkin, S. W. Oh, H. A. Zariwala, H. Gu, L. L. Ng, R. D. Palmiter, M. J. Hawrylycz, A. R. Jones, E. S. Lein, H. Zeng, A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* **13**, 133–140 (2010). Medline doi:10.1038/nn.2467
  16. Materials and methods are available as supplementary materials on Science Online.
  17. P. Sicinski, Y. Geng, A. S. Ryder-Cook, E. A. Barnard, M. G. Darlison, P. J. Barnard, The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. *Science* **244**, 1578–1580 (1989). Medline doi:10.1126/science.2662404
  18. C. Xu, M. Tabebordbar, S. Iovino, C. Ciarlo, J. Liu, A. Castiglioni, E. Price, M. Liu, E. R. Barton, C. R. Kahn, A. J. Wagers, L. I. Zon, A zebrafish embryo culture system defines factors that promote vertebrate myogenesis across species. *Cell* **155**, 909–921 (2013). Medline doi:10.1016/j.cell.2013.10.023
  19. F. A. Ran, L. Cong, W. X. Yan, D. A. Scott, J. S. Gootenberg, A. J. Kriz, B. Zetsche, O. Shalem, X. Wu, K. S. Makarova, E. V. Koonin, P. A. Sharp, F. Zhang, In vivo genome editing using *Staphylococcus aureus* Cas9. *Nature* **520**, 186–191 (2015). Medline doi:10.1038/nature14299
  20. C. Zincarelli, S. Soltys, G. Rengo, J. E. Rabinowitz, Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. *Mol. Ther.* **16**, 1073–1080 (2008). Medline doi:10.1038/mt.2008.76
  21. Q. L. Lu, G. E. Morris, S. D. Wilton, T. Ly, O. V. Artem'yeva, P. Strong, T. A. Partridge, Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. *J. Cell Biol.* **148**, 985–996 (2000). Medline doi:10.1083/jcb.148.5.985
  22. D. Bosnakovski, Z. Xu, W. Li, S. Thet, O. Cleaver, R. C. Perlingeiro, M. Kyba, Prospective isolation of skeletal muscle stem cells with a Pax7 reporter. *Stem Cells* **26**, 3194–3204 (2008). Medline doi:10.1634/stemcells.2007-1017
  23. M. van Putten, E. M. van der Pijl, M. Hulsker, I. E. Verhaart, V. D. Nadarajah, L. van der Weerd, A. Aartsma-Rus, Low dystrophin levels in heart can delay heart failure in mdx mice. *J. Mol. Cell. Cardiol.* **69**, 17–23 (2014). Medline doi:10.1016/j.yjmcc.2014.01.009
  24. M. van Putten, M. Hulsker, C. Young, V. D. Nadarajah, H. Heemskerk, L. van der Weerd, P. A. 't Hoen, G. J. van Ommen, A. M. Aartsma-Rus, Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. *FASEB J.* **27**, 2484–2495 (2013). Medline doi:10.1096/fj.12-224170
  25. M. van Putten, M. Hulsker, V. D. Nadarajah, S. H. van Heiningen, E. van Huizen, M. van IJterson, P. Admiraal, T. Messemaker, J. T. den Dunnen, P. A. 't Hoen, A. Aartsma-Rus, The effects of low levels of dystrophin on mouse muscle function and pathology. *PLOS ONE* **7**, e31937 (2012). Medline doi:10.1371/journal.pone.0031937
  26. C. Long, J. R. McAnally, J. M. Shelton, A. A. Mireault, R. Bassel-Duby, E. N. Olson, Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. *Science* **345**, 1184–1188 (2014). Medline doi:10.1126/science.1254445
  27. M. Neri, S. Torelli, S. Brown, I. Ugo, P. Sabatelli, L. Merlini, P. Spitali, P. Rimessi, F. Gualandi, C. Sewry, A. Ferlini, F. Muntoni, Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. *Neuromuscul. Disord.* **17**, 913–918 (2007). Medline doi:10.1016/j.nmd.2007.07.005
  28. P. D. Hsu, D. A. Scott, J. A. Weinstein, F. A. Ran, S. Konermann, V. Agarwala, Y. Li, E. J. Fine, X. Wu, O. Shalem, T. J. Cradick, L. A. Marraffini, G. Bao, F. Zhang, DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat. Biotechnol.* **31**, 827–832 (2013). Medline doi:10.1038/nbt.2647
  29. M. Cerletti, S. Jurga, C. A. Witczak, M. F. Hirshman, J. L. Shadrach, L. J. Goodyear, A. J. Wagers, Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. *Cell* **134**, 37–47 (2008). Medline doi:10.1016/j.cell.2008.05.049
  30. R. I. Sherman, J. L. Christensen, I. M. Conboy, M. J. Conboy, T. A. Rando, I. L. Weissman, A. J. Wagers, Isolation of adult mouse myogenic progenitors: Functional heterogeneity of cells within and engrafting skeletal muscle. *Cell* **119**, 543–554 (2004). Medline doi:10.1016/j.cell.2004.10.021
  31. L. V. Anderson, K. Davison, Multiplex Western blotting system for the analysis of muscular dystrophy proteins. *Am. J. Pathol.* **154**, 1017–1022 (1999). Medline doi:10.1016/S0002-9440(10)65354-0
  32. L. V. Nicholson, K. Davison, G. Falkous, C. Harwood, E. O'Donnell, C. R. Slater, J. B. Harris, Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody. *J. Neurol. Sci.* **94**, 125–136 (1989). Medline doi:10.1016/0022-510X(89)90223-2
  33. T. J. Burkholder, B. Fingado, S. Baron, R. L. Lieber, Relationship between muscle fiber types and sizes and muscle architectural properties in the mouse hindlimb. *J. Morphol.* **221**, 177–190 (1994). Medline doi:10.1002/jmor.1052210207
  34. J. Mendez, A. Keyes, Density and composition of mammalian muscle. *Metabolism* **9**, 184–188 (1960).
  35. V. Straub, R. E. Bittner, J. J. Léger, T. Voit, Direct visualization of the dystrophin network on skeletal muscle fiber membrane. *J. Cell Biol.* **119**, 1183–1191 (1992). Medline doi:10.1083/jcb.119.5.1183
  36. K. P. Campbell, S. D. Kahl, Association of dystrophin and an integral membrane glycoprotein. *Nature* **338**, 259–262 (1989). Medline doi:10.1038/338259a0
  37. A. Sacco, F. Mourkioti, R. Tran, J. Choi, M. Llewellyn, P. Kraft, M. Shkrel, S. Delp, J. H. Pomerantz, S. E. Artandi, H. M. Blau, Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. *Cell* **143**, 1059–1071 (2010). Medline doi:10.1016/j.cell.2010.11.039
  38. N. A. Dumont, Y. X. Wang, J. von Maltzahn, A. Pasut, C. F. Bentzinger, C. E. Brun, M. A. Rudnicki, Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. *Nat. Med.* **21**, 1455–1463 (2015). Medline doi:10.1038/nm.3990

39. Q. L. Lu, S. Cirak, T. Partridge, What can we learn from clinical trials of exon skipping for DMD? *Mol. Ther. Nucleic Acids* **3**, e152 (2014). Medline doi:10.1038/mtna.2014.6
40. H. Yin, A. F. Saleh, C. Betts, P. Camelliti, Y. Seow, S. Ashraf, A. Arzumanov, S. Hammond, T. Merritt, M. J. Gait, M. J. Wood, Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. *Mol. Ther.* **19**, 1295–1303 (2011). Medline doi:10.1038/mt.2011.79
41. M. Le Hir, A. Goyenvalle, C. Peccate, G. Précigout, K. E. Davies, T. Voit, L. Garcia, S. Lorain, AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy. *Mol. Ther.* **21**, 1551–1558 (2013). Medline doi:10.1038/mt.2013.121
42. K. M. Flanigan, D. M. Dunn, A. von Niederhausern, P. Soltanzadeh, E. Gappmaier, M. T. Howard, J. B. Sampson, J. R. Mendell, C. Wall, W. M. King, A. Pestronk, J. M. Florence, A. M. Connolly, K. D. Mathews, C. M. Stephan, K. S. Laubenthal, B. L. Wong, P. J. Morehart, A. Meyer, R. S. Finkel, C. G. Bonnemann, L. Medne, J. W. Day, J. C. Dalton, M. K. Margolis, V. J. Hinton, R. B. Weiss; United Dystrophinopathy Project Consortium, Mutational spectrum of DMD mutations in dystrophinopathy patients: Application of modern diagnostic techniques to a large cohort. *Hum. Mutat.* **30**, 1657–1666 (2009). Medline doi:10.1002/humu.21114
43. C. Bérout, S. Tuffery-Giraud, M. Matsuo, D. Hamroun, V. Humbertclaude, N. Monnier, M. P. Moizard, M. A. Voelckel, L. M. Calemard, P. Boisseau, M. Blayau, C. Philippe, M. Cossée, M. Pagès, F. Rivier, O. Danos, L. Garcia, M. Claustres, Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. *Hum. Mutat.* **28**, 196–202 (2007). Medline doi:10.1002/humu.20428
44. M. A. Kotterman, D. V. Schaffer, Engineering adeno-associated viruses for clinical gene therapy. *Nat. Rev. Genet.* **15**, 445–451 (2014). Medline doi:10.1038/nrg3742
45. F. Mingozzi, K. A. High, Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. *Nat. Rev. Genet.* **12**, 341–355 (2011). Medline doi:10.1038/nrg2988
46. C. E. Nelson, C. H. Hakim, D. G. Ousterout, P. I. Thakore, E. A. Moreb, R. Castellanos, S. Madhavan, X. Pan, F. A. Ran, W. X. Yan, A. Asokan, F. Zhang, D. Duan, C. A. Gersbach, In vivo genome editing improves muscle function in a model of Duchenne muscular dystrophy. *Science* **350**, aad5143 (2015).
47. E. Zinn, S. Pacouret, V. Khaychuk, H. T. Turunen, L. S. Carvalho, E. Andres-Mateos, S. Shah, R. Shelke, A. C. Maurer, E. Plovie, R. Xiao, L. H. Vandenberghe, In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector. *Cell Reports* **12**, 1056–1068 (2015). Medline doi:10.1016/j.celrep.2015.07.019
48. Z. Wu, H. Yang, P. Colosi, Effect of genome size on AAV vector packaging. *Mol. Ther.* **18**, 80–86 (2010). Medline doi:10.1038/mt.2009.255
49. J. Y. Dong, P. D. Fan, R. A. Frizzell, Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. *Hum. Gene Ther.* **7**, 2101–2112 (1996). Medline doi:10.1089/hum.1996.7.17-2101
50. S. Nielsen, Y. Yuzenkova, N. Zenkin, Mechanism of eukaryotic RNA polymerase III transcription termination. *Science* **340**, 1577–1580 (2013). Medline doi:10.1126/science.1237934
51. B. Chen, L. A. Gilbert, B. A. Cimini, J. Schnitzbauer, W. Zhang, G. W. Li, J. Park, E. H. Blackburn, J. S. Weissman, L. S. Qi, B. Huang, Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. *Cell* **155**, 1479–1491 (2013). Medline doi:10.1016/j.cell.2013.12.001
52. L. S. Ostedgaard, T. Rokhlina, P. H. Karp, P. Lashmit, S. Afione, M. Schmidt, J. Zabner, M. F. Stinski, J. A. Chiorini, M. J. Welsh, A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 2952–2957 (2005). Medline doi:10.1073/pnas.0409845102
53. O. Shalem, N. E. Sanjana, E. Hartenian, X. Shi, D. A. Scott, T. S. Mikkelsen, D. Heckl, B. L. Ebert, D. E. Root, J. G. Doench, F. Zhang, Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* **343**, 84–87 (2014). Medline doi:10.1126/science.1247005
54. A. L. Arnett, P. Konieczny, J. N. Ramos, J. Hall, G. Odom, Z. Yablonka-Reuveni, J. R. Chamberlain, J. S. Chamberlain, Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. *Mol. Ther. Methods Clin. Dev.* **1**, 14038 (2014). Medline doi:10.1038/mtm.2014.38


## ACKNOWLEDGMENTS

We thank the HSCI/HSCRB Flow Cytometry Core, the SERI/MEEI Gene Transfer Vector Core, the Parker lab at Harvard and J. Goldstein for technical assistance. Work was funded in part by grants from HHMI and NIH (1DP2OD004345, 5U01HL100402, 5PN2EY018244) to A.J.W. M.T. is an Albert J. Ryan fellow. F.A.R. is a Junior Fellow at the Harvard Society of Fellows. W.X.Y. was supported by T2GM007753 from the National Institute of General Medical Sciences (NIGMS), NIH. F.Z. is a New York Stem Cell Foundation Robertson Investigator and supported by National Institute of Mental Health, NIH (5DP1-MH100706) and National Institute of Diabetes and Digestive and Kidney Diseases, NIH (5R01DK097768-03), a Waterman Award from the National Science Foundation, the Keck, New York Stem Cell, Damon Runyon, Searle Scholars, Merkin, and Vallee Foundations, and B. Metcalfe. W.L.C. is supported by the National Science Scholarship from the Agency for Science, Technology, and Research (A\*STAR), Singapore. G.M.C. is supported for this work by National Human Genome Research Institute (NIGMS), NIH, Centers of Excellence in Genomic Science, P50 HG005550. Content is solely the responsibility of the authors and does not necessarily represent the official views of NIGMS or NIH. M.T., A.J.W., W.L.C., and G.M.C. are inventors on a patent application (PCT/US15/63181) filed by Harvard University related to in vivo genetic modifications and gene editing in muscle. G.M.C. is an inventor on issued patents (US9023649, US9074199) filed by Harvard University related to CRISPR. L.H.V. is an inventor on a patent application (US2007036760) filed by the University of Pennsylvania related to AAV capsid sequences. F.Z., L.C., F.A.R., and W.Y. are inventors on patents and patent applications (8,865,406; 8,906,616; and accepted EP 2898075, from International patent application WO 2014/093635) filed by the Broad Institute related to SaCas9 optimized components and systems. A.J.W. is an advisor for Fate Therapeutics. G.M.C. and F.Z. are founders and scientific advisors of Editas Medicine, and F.Z. is a scientific advisor for Horizon Discovery. G.M.C. has equity in Caribou/Intellia, Egenesis, and Editas (for full disclosure list, see: <http://arep.med.harvard.edu/gmc/tech.html>). L.H.V. is cofounder, shareholder, member of the Scientific Advisory Board, and consultant of GenSight Biologics, a consultant to Novartis and Eleven Bio, and received honoraria and consulting fees from Regeneron Pharmaceuticals and Cowen, Jefferies, and Sectoral. AAV9 vector sequences are available through a material transfer agreement (MTA) from the University of Pennsylvania. Sa Cas9 plasmids are openly available through a Uniform Biological MTA from Addgene.


## SUPPLEMENTARY MATERIALS

[www.sciencemag.org/cgi/content/full/science.aad5177/DC1](http://www.sciencemag.org/cgi/content/full/science.aad5177/DC1)  
Materials and Methods  
Supplementary Text  
Figures S1 to S12  
Tables S1 to S4  
References (28–54)

23 September 2015; accepted 08 December 2015  
Published online 31 December 2015  
10.1126/science.aad5177




**Fig. 1. DYSTROPHIN expression in CRISPR-modified dystrophic satellite cells.** (A) Detection of exon23 excision by genomic PCR in myotubes derived from satellite cells transfected with SpCas9 and Ai9 gRNAs (left lanes) or coupled Ai9-Dmd23 gRNAs (right lanes). Unedited genomic product, 1572bp; gene-edited product (red asterisk), 1189bp. M, molecular weight marker. (B) RT-PCR detection of exon23-deleted mRNA. Unedited RT-PCR product: 738bp; exon23-deleted product (blue asterisk): 525bp. (C) Western blot detecting DYSTROPHIN in myotubes derived from gene-edited satellite cells. A.U.: Arbitrary Unit, normalized to GAPDH (loading control). DYS: DYSTROPHIN, WT: wild type (D) DYSTROPHIN immunofluorescence in *mdx* muscles transplanted with satellite cells transfected ex vivo with SpCas9 + Ai9 gRNAs (top) or SpCas9 + Ai9-Dmd23 coupled gRNAs (bottom). For merge: Green: DYSTROPHIN; Red: tdTomato; Blue: DAPI (nuclei). Scale bar: 200  $\mu$ m. See also fig. S11.




**Fig. 2. AAV-CRISPR enables in vivo excision of *Dmd* exon23 and restores DYSTROPHIN expression in adult dystrophic muscle.** (A and B) Detection of exon23 excision in TA muscles from *mdx*;*Ai9* mice injected intramuscularly with AAV-Ai9 CRISPR (left lanes) or AAV-*Dmd* CRISPR (right lanes) by genomic PCR (A) unedited product 1012bp; exon-excised product 470bp and RT-PCR (B). Asterisks mark gene-edited bands. M, molecular weight marker. (C) Western blot detecting DYSTROPHIN in muscles injected with AAV-Ai9 CRISPR (left) or AAV-*Dmd* CRISPR (right), with relative signal intensity determined by densitometry at bottom. A.U.: Arbitrary Unit, normalized to GAPDH. (D) Representative immunofluorescence images for DYSTROPHIN (green) and DAPI (blue) in *mdx*;*Ai9* muscles injected with AAV-Ai9 (left) or AAV-*Dmd* (right) CRISPR. Scale bar: 500  $\mu$ m. (E and F) Muscle specific force (E) and decrease in force after eccentric damage (F) for wild type mice injected with vehicle ( $n = 9$ ), *mdx*;*Ai9* mice injected with AAV-*Dmd* CRISPR in the right TA and vehicle in the left TA ( $n = 12$ ), *mdx*;*Ai9* mice injected with AAV-Ai9 CRISPR in the right TA and vehicle in the left TA ( $n = 12$ ). \* $P < 0.05$ , \*\* $P < 0.01$ , n.s., not significant, one-way ANOVA with Newman-Keuls multiple comparisons test.





**Fig. 3. Systemic dissemination of AAV-CRISPR targets *Dmd* exon23 and restores DYSTROPHIN in dystrophic cardiac and skeletal muscles.** (A) Exon23-deleted transcripts in muscles quantified by Taqman. Data plotted for individual mice [ $n = 7$  receiving AAV-*Dmd* CRISPR (blue) and  $n = 3$  receiving AAV-Ai9 CRISPR (red)] and overlaid with mean  $\pm$  SEM. (B) Western blots detecting DYSTROPHIN in the indicated muscles of *mdx;Ai9* mice receiving systemic AAV-CRISPR. Right lanes correspond to muscles from seven different mice injected intraperitoneally with AAV-*Dmd* CRISPR. Relative signal intensity, determined by densitometry, presented as A.U.: Arbitrary Unit normalized to GAPDH. (C) Representative immunofluorescence staining for DYSTROPHIN (green) in *mdx;Ai9* mice injected with AAV-Ai9 (top) or AAV-*Dmd* (bottom) CRISPR. Blue: DAPI (nuclei). Scale bar: 200  $\mu$ m.





**Fig. 4. Satellite cells in dystrophic muscles are transduced and targeted with systemically disseminated AAV-CRISPR.** (A) Experimental design. (B) Percent of ZsGreen<sup>+</sup> satellite cells expressing tdTomato<sup>+</sup> after intraperitoneal injection of *Pax7-ZsGreen+/-;mdx;Ai9* mice. Individual data points overlaid with mean  $\pm$  SD; vehicle ( $n = 3$ ), AAV-Cre ( $n = 4$ ) AAV Ai9 CRISPR ( $n = 5$ ). (C) Representative immunofluorescence of myotubes differentiated from FACSsorted satellite cells from mice injected intraperitoneally with vehicle, AAV-Cre, or AAV-Ai9 CRISPR. Green: Myosin heavy chain (MHC); Red: tdTomato. Blue: DAPI (nuclei) Scale bar: 200  $\mu$ m. (D) Exon23-deleted DMD mRNA in satellite-cell derived myotubes from mice previously injected intraperitoneally with AAV-*Dmd* CRISPR (right lanes), compared to control AAV-Ai9 CRISPR (left lanes).